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CORRESPONDENCE
Access to fluconazole in
less-developed countries
Sir—When  life-saving  medicines  are
unaffordable  because  of  high  prices
resulting  from  exclusive  marketing
rights  (patents),  intellectual  property
protection threatens people’s health. If
the price of medicines puts them out of
reach  of  those  in  need,  national
governments should be encouraged to
produce or import generic versions, as
is their right within international World
Trade  Organisation  agreements.
1 This
issue has been highlighted through the
high  price  of  fluconazole  in  South
Africa.
2 Médecins  Sans  Frontières
(MSF)  assessed  the  price  variation  of
fluconazole and investigated alternative
sources in different countries to help to
increase  access  to  life-saving  drugs.
Affordable  fluconazole  has  been
introduced  in  MSF  projects  in
Cambodia and Guatemala. We would
like  to  extend  this  example  to  other
countries.
Fluconazole  is  a  key  drug  in  the
treatment  of  cryptococcal  meningitis.
This disorder affects around one in ten
people  who  have  AIDS.  In  some
countries, the prevalence is up to 25%.
Without  treatment,  life  expectancy  is
less than 1 month. The recommended
regimen is 400 mg fluconazole daily for
12  weeks,  followed  by  lifelong
maintenance therapy (200 mg daily).
3
In  many  countries  that  recognise
medicine  patents,  Pfizer  has  had  a
market  monopoly  for  fluconazole  for
the past 12 years. Their patent will not
expire  before  2004  in  the  USA  and
even  later  in  some  countries.
Worldwide sales of Pfizer’s fluconazole
made  US$1002  million  in  1999
(www.pfizer.com  accessed  Nov  28,
2000). Pfizer sells fluconazole in less-
developed countries at the same prices
as  those  in  more-developed  countries
and has so far refused to offer voluntary
licences in poor countries so that other
health  ministeries  could  arrange  for
production  or  importation  of  an
affordable generic supply.
We  limited  the  study  to  eight
countries  where  MSF  runs  HIV  and
AIDS programmes or that produce, and
so could supply, fluconazole. In those
countries  where  fluconazole  is  not
patented,  we  obtained  generic  and
Pfizer’s private wholesale prices. In all
cases, generic drug supplies came from
manufacturers  that  have  Good
Manufacturing  Practices  approval  and
have  their  product  registered  in  the
country  of  origin.  The  comparison  of
prices  is  shown  in  the  table.  If  South
Africa  were  to  import  generic
fluconazole from Thailand, the cost of 1
year’s  maintenance  treatment  would
drop from $2970 to $104. This change
would have a striking effect on access
and adherence to treatment.
In  less-developed  countries,  where
fluconazole  is  patent-protected,  Pfizer
should lower the price to generic levels
so that people can access this life-saving
treatment, but so far has refused to do
so.  In  South  Africa,  the  Treatment
Access  Campaign  (a  local  activist
group) asked for a price reduction or a
voluntary  licence  to  allow  generic
production. This request was supported
internationally  by  MSF.  Pfizer
responded by announcing that it would
provide a donation,
4 but no drug has yet
reached patients.
An  adequate  response  to  the
overwhelming  burden  of  infectious
diseases will never be possible through
limited  donations  from  multinational
pharmaceutical companies. Ultimately,
the power to ensure access to affordable
essential  medicines  remains  with
national governments that can negotiate
prices  based  on  comparative  price 
data,  register  generic  producers 
when  possible,  and  issue  compulsory
licences  when  necessary.  International
organisations  such  as  WHO  and
UNAIDS  have  an  important  role 
in  gathering  objective  price  data 
and  providing  technical  support  to 
activate  World  Trade  Organisation
safeguards  to  override  patents  when
necessary.
*Carmen Perez-Casas, Pierre Chirac,
Daniel Berman, Nathan Ford
Médecins Sans Frontières, 1211 Geneva,
Switzerland
(e-mail: access@geneva.msf.org)
1 WHO. Globalization and Access to Drugs:
implications of the WTO/TRIPS
agreement/WHO/DAP.98.9. Geneva: WHO,
1997.
2 Baleta A. AIDS activists force attention to
fluconazole in South Africa. Lancet 2000;
356: 1584.
3 WHO, Drugs used in HIV-related infections,
WHO model prescribing information,
DMP/DSI/99.2, Geneva: WHO, 1999.
4 Waldholz M. Pfizer plans to provide
Diflucan drug at no cost to South Africans
with AIDS. Wall Street Journal 2000;
March 4.
Health and human rights
Sir—We  are  surprised  that  Richard
Horton,  in  his  report  (Sept  30,
p 1186),
1 suggests that those who work
in the health professions should join the
debate  on  domestic  health  issues  as
energetically  as  they  have  that  on
human rights issues abroad.
Physicians for Human Rights (PHR-
UK) is committed to the protection of
human  rights  wherever  they  may  be
threatened.  We  have  focused  on
countries  such  as  Rwanda,  Kashmir,
Palestine,  Armenia,  Egypt,  South
Africa, and Kuwait, as well as the UK.
We  welcome  your  prescription  that
the  European  Convention  on  Human
Rights should be amended to include a
statement  about  health  as  a  basic
enforceable  right.  With  a  reported
12000  petitions  pending  before  the
European  Court  of  Human  Rights,
however, a reform of that nature in the
near future is difficult to envisage. We
think  that  consideration  should  be
given  to  other  human  rights
instruments.
The  European  Convention’s  sister
treaty, the European Social Charter of
1961,  makes  provision  for  health  in
Articles  11  and  13,  with  special
provision for elderly people in Article 4
of  its  1988  additional  protocol.  The
Charter  has  been  amended  to  permit
complaints  by  non-governmental
organisations  such  as  human  rights
groups.
A  further  measure  is  the  UN
Covenant  on  Economic,  Social  and
Cultural Rights. The UK last reported
to  the  UN  on  its  progress  in
implementing this treaty, in November,
1997. At that time, several UK human
rights  organisations  produced  a  joint
response  to  the  Government’s  report
that  discussed  correlations  between
health  and  poverty,  the  rise  in
psychosocial  disorders  among  young
people,  and  the  impact  of  National
Health  Service  identity  checks  on
people seeking medical attention. The
UN  Committee  on  Economic,  Social
and  Cultural  Rights  has  provided
detailed guidance on how UK citizens
can  draw  the  attention  of  the
Committee  to  any  shortcomings  they
perceive in the UK’s implementation of
the covenant.
We believe that greater awareness of
the  existing  international  mechanisms
and a readiness to use them is needed.
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Manufacturer  Country of Price per
(country distribution unit 
of production) (US$)
Biolab (Thailand) Thailand 0·29
Cipla (India) India 0·64
Bussie (Colombia) Guatemala (negotiated) 3·00
Pfizer Thailand 6·20
Vita (Spain) Spain 6·29
Pfizer South Africa 8·25
Pfizer Kenya 10·50
Pfizer Spain 10·57
Pfizer Guatemala (negotiated) 11·84
Pfizer USA 12·20
Pfizer Guatemala (not negotiated)27·60
Wholesale prices of 200 mg fluconazole
capsules in June, 2000